The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer-Reference-Cited by-同舟云学术

The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer

Published:2018-02-10 Issue:2 Volume:16 Page:
ISSN:1726-913X
Container-title:International Journal of Endocrinology and Metabolism
language:
Short-container-title:Int J Endocrinol Metab

Author:

Zarkesh Maryam,Zadeh-Vakili Azita,Azizi Fereidoun,Fanaei S Ahmad,Foroughi Forough,Hedayati Mehdi

Publisher

Briefland

Subject

Endocrinology, Diabetes and Metabolism

Reference38 articles.

1. Thyroid Cancer Epidemiology and Prognostic Variables

2. International patterns and trends in thyroid cancer incidence, 1973–2002

3. BRAF mutation in thyroid cancer

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma;Endocrine;2024-06-17

2. RET/PTC rearrangement in papillary thyroid carcinoma arising in malignant struma ovarii with abdominal wall metastasis and cervical thyroid gland: a case report and review of the literature;Thyroid Research;2023-09-27

3. Budding uninhibited by benzimidazoles 1 might be a poor prognosis biomarker promoting the progression of papillary thyroid cancer;Environmental Toxicology;2023-05-10

4. RET/PTC rearrangement in papillary thyroid carcinoma arising in malignant struma ovarii with abdominal wall metastasis and cervical thyroid gland: A case report and review of the literature;2023-01-03

5. CpG island status as an epigenetic alteration for NIS promoter in thyroid neoplasms; a cross-sectional study with a systematic review;Cancer Cell International;2022-10-11